https://www.selleckchem.com/pr....oducts/zotatifin.htm
We previously demonstrated that **** influences response to immune checkpoint inhibitors. In this article, we investigate ****-based differences in the molecular mechanisms of anticancer immune response and immune evasion in patients with NSCLC. We analyzed (i) transcriptome data of 2,575 early-stage NSCLCs from seven different datasets; (ii) 327 tumor samples extensively characterized at the molecular level from the TRACERx lung study; (iii) two independent cohorts of 329 and 391 patients, respectively, with advanced NSCLC treated with
Like
Comment
Share
